OSE Immunotherapeutics last night reported new positive phase 1/2 data in advanced solid tumors, which supported its share price on Tuesday on the Paris stock exchange.

These results, presented at the ESMO congress dedicated to targeted cancer therapies currently taking place in Paris, notably show a good pharmacokinetic and pharmacodynamic profile.

They also show an acceptable safety profile, in line with previous anti-PD1 development, and a high efficacy signal in the first 20 patients representing 13 different tumor types, OSE points out.

Four ongoing partial responses, at a dose of 600 mg every six weeks with a response rate of 36%, have been confirmed in patients with anal squamous cell carcinoma, undifferentiated pleomorphic sarcoma, oncocytic thyroid cancer and alveolar soft-tissue sarcoma.

Following these announcements, OSE Immunotherapeutics shares gained over 5% on Tuesday on the Paris Bourse.

OSE-279 is a humanized anti-PD1 monoclonal antibody that blocks both PD-L1 and PD-L2 ligands, overexpressed in tumor cells and the tumor microenvironment.

As a reminder, OSE Immuno's objective is to develop an anti-PD-1 to address, as a priority, niche indications not targeted by Big Pharmas", say analysts at Invest Securities.

Final results from this Phase I/II trial are expected in the third quarter of 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.